The antibiotic is sold in Europe by Pfizer under the Zavicefta brand name and got a green light from the EMA in 2016. ... Zavicefta is already approved in Europe for HABP/VABP. One of the key roles for the new product is in the treatment of infections

Meanwhile, Pfizer’s new antibiotic for multidrug resistant (MDR) infections, Zavicefta, was launched in its first European markets earlier this year after the pharma firm paid its developer AstraZeneca $1.58bn

The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year. ... The availability of Zavicefta is a major step forward for

The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and